One-Third Less: Tirzetta®—Russia’s First Tirzepatide—Now More Affordable for Patients
PROMOMED, a leading Russian manufacturer of innovative treatments for obesity and type 2 diabetes, has announced a 33% price reduction for Tirzetta®—the first tirzepatide-based medication available on the Russian market.
Tirzetta® is a sought-after domestic alternative to the American drug Mounjaro®, used for weight reduction and lowering the risk of developing type 2 diabetes. Its active ingredient, tirzepatide, represents a new class of dual incretin agonists that simultaneously activate two key metabolism-regulating receptors: GIP and GLP-1. This combined action ensures a highly selective effect on metabolic regulation, insulin and glucose levels, and the rate of metabolism in body tissues and organs. Weight loss occurs while preserving muscle mass, resulting in a physiologically balanced and aesthetically pleasing body contour.
Both Tirzetta® and Mounjaro®, the latter being a US product, feature an innovative molecule and are free from preservatives.
Tirzetta® is produced entirely in-house by PROMOMED—from API to finished dosage form. It is available as a solution for subcutaneous injection in convenient, single-use, intuitive auto-injectors in the following dosages: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
“According to official statistics, 40 million people in Russia suffer from obesity, and 60 million are overweight. Obesity is not just an aesthetic issue—it’s a serious health risk factor, including for cardiovascular disease and cancer. This is a national-scale problem that calls for modern, effective therapy.
Production volumes of Tirzetta® have increased. Technological improvements and cost optimization in large-scale manufacturing have enabled us to make the product even more accessible in response to the growing demand for effective, long-term weight loss solutions. By responding to the needs of each individual patient and the broader medical community today, we are helping prevent disease—and ultimately, cure previously untreatable conditions tomorrow,”
noted Lyudmila Kovalchuk, Director of Marketing and Sales for the Endocrinology division at PROMOMED.
The new price for takes effect starting May 6, 2025, and applies to the entire Tirzetta® product line.
